Friday, November 13, 2020

Think Bigger Capital launches its first fund with a target size of €30m.

MADRID, Nov. 13, 2020 /PRNewswire/ -- Think Bigger Capital, Demium's Asset Management Company announces its first fund (TBF I) which has a target size of €30M and focuses on investing in technology and innovation companies in Europe.

The fund invests at least €100K of pre-seed funding for an equity stake in each company that completes the Demium's incubation programme and is selected by the investment committee. The asset manager's selection criteria are independent of those of Demium Startups.

Selected teams will receive mentoring and assistance with their project to best prepare them to qualify for pre-seed investment with Demium's asset management company.

Currently, the company has raised 78% of the fund's target size. Anchor investors include  Fond-ICO Global, the first public venture capital "Fund of Funds" to be created in Spain and the IVF (Institute Valencià de Finances) Fund Program for high growth ICT based startups (with the participation of FEDER - Fondo Europeo de Desarrollo Regional). The Fund also counts on multiple Spanish and European Family offices among its Limited Partners.  Demium's partner fund plans to invest €100K in 150 startups, and reserves an additional 37.5% of the fund for follow-on investments.

The Asset Management Company is run by Alvaro Villacorta Previously, Mr. Villacorta founded and ran Food Messenger, a food-delivery company acquired by Rocket Internet in 2015 and has worked with Demium since 2017 -- most recently as its Vice-President of Incubation. Luis Martínez-Curt, Nicolás Gerardi and  Santiago Reyna complete the Board of Directors. Additionally, Jorge Dobon -- Demium's Founder and Executive Chairman -- sits on the Fund's Investment committee.

Raising TBC I is a first step in the company's strategy to raise a family of regional funds to invest in Startups in Spain, Portugal, Greece and Eastern Europe.

About Think Bigger Capital

Think Bigger Capital S.G.E.I.C, subsidiary of Demium, is a spanish venture capital firm based in Spain (approved by CNMV regulator, under number 163). Their mission is to help create successful companies with the most talented entrepreneurs worldwide.

About Demium

Demium is an International Startup Builder currently based in Valencia, Madrid, Barcelona, Malaga, Lisbon, Kyiv, Warsaw and Athens. At Demium they create startups from scratch. That means that they work with budding entrepreneurs before they've even uttered an idea, let alone launched one.

SOURCE Think Bigger Capital


Thursday, November 12, 2020

Horizon Technology Finance Provides $25 Million Venture Loan Facility to Getaround

FARMINGTON, Conn., Nov. 12, 2020 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, announced today it has provided a $25 million venture loan facility to Getaround, Inc. ("Getaround").

Getaround provides a peer-to-peer car sharing platform where individuals can share their car by the day or the hour, tapping into the 22+ hours per day most cars sit idle and disrupting the $100 billion global rental and mobility markets.  Getaround has become a recognized leader in car sharing, growing its presence to over 300 U.S. and European cities, and is backed by premier tech investors including Reinvent Capital, PeopleFund, Softbank Vision Fund, Menlo Ventures and Braemar Energy Ventures. Getaround will use the loan proceeds for general working capital purposes.

"Getaround is changing the way people think about renting and sharing cars through their seamless and easy-to-use technology platform," said Gerald A. Michaud, President of Horizon. "They have done an excellent job adapting to the current challenging environment and their innovative technology leaves them poised to embark on their next phase of growth. We are excited to support Getaround as they progress toward becoming a global leader in mobility." 

"We are very appreciative of Horizon's support and confidence in Getaround being the future of mobility," said Sam Zaid, Founder and Chief Executive Officer at Getaround. "Our pioneering contactless solution enables people across the globe to carshare safely during the pandemic. Horizon's investment will help us further accelerate our growth."

Armentum Partners served as financial advisor to Getaround in connection with this financing.

About Horizon Technology Finance

Horizon Technology Finance Corporation (NASDAQ: HRZN) is a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio's return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Headquartered in Farmington, Connecticut, Horizon also has regional offices in Pleasanton, California and Reston, Virginia. To learn more, please visit

About Getaround, Inc.

Getaround empowers people to instantly access and drive great cars shared by people in their city. Cars can be rented by the hour, or the day, with insurance included. By using the Getaround app, people skip the lines and paperwork at traditional rental car counters, and the hassle of buying and maintaining a car.

Powered by Getaround ConnectⓇ, the proprietary connected car technology, Getaround creates a fun and safe carsharing experience without the need to meet the car owner, carry an access card, or coordinate picking up a car key. People share everything from a Prius to a Tesla and earn up to thousands in extra income each year, offsetting the high cost of car ownership while also making a positive impact on the environment.

Headquartered in San Francisco, Getaround is the world's largest connected carsharing marketplace with thousands of cars available in over 300 cities across the U.S. and Europe. For more information visit, download the iPhone or Android app, like on Facebook, and follow on Instagram and Twitter.

Forward-Looking Statements

Statements included herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in the Company's filings with the Securities and Exchange Commission. Horizon undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.


Investor Relations:
Garrett Edson
[email protected]
(860) 284-6450

Media Relations:
Chris Gillick
[email protected]    
(646) 677-1819

SOURCE Horizon Technology Finance Corporation

Related Links


OSF Ventures Invests in Specialized Therapy Company; Plans Pilot for Children with Autism

PEORIA, Ill., Nov. 12, 2020 /PRNewswire/ -- OSF Ventures has joined an early round of funding for Madison, Wisconsin-based DotCom Therapy, a therapist-founded company specializing in skilled, face-to-face, online therapy services. Speech language pathologist Rachel Robinson founded the company in 2015 as a solution to widespread therapy shortages for children across the country.

"We really saw value in a company that is filling the need for mandated special education services required for 14% of all public school children across the country," said Stan Lynall, vice president for OSF Venture Investments. "In many cases, video visits supplement what the schools are able to provide through their own, school-based therapists." Lynall added, "We are excited to partner with DotCom Therapy as they expand their service offerings to health care systems."

DotCom Therapy provides services to more than 250 schools across the U.S. It offers mental health counseling, speech therapy, occupational therapy, and behavioral health services. OSF Ventures joins New Capital Partners in the Series A funding to grow DCT's customer base and scale their services into health care systems such as Peoria-Illinois-based OSF HealthCare which will launch a pilot using Dotcom Therapy for children who are on the autism spectrum.

Cheryl Crowe, vice president for Behavioral Health at OSF HealthCare says DotCom Therapy will provide support for children who have been diagnosed with Autism Spectrum Disorder (ASD), a neurological and developmental disorder that begins in early childhood.

The pilot will be coordinated through OSF Saint Francis Medical Center and Children's Hospital of Illinois in Peoria. "A DotCom Board Certified Behavior Analyst will provide services to advance behavioral modification, social and emotional control, and parent education," according to Crowe. "We will also utilize a Licensed Clinical Social Worker who has experience working with individuals with Autism Spectrum Disorder. They will be working with both the children and their families on coping and other important life skills."

With so many children learning at home, Crowe says now is an ideal time to implement a web-based therapy strategy.

"This will enable us to provide children with a comfortable setting with people they trust, plus research shows children with ASD are fascinated by computers and benefit from tech-based intervention." She continued, "Video visits will also allow therapists to educate parents and trouble-shoot situations in real-time to address communication deficits secondary to autism in a functional, flexible way."

"We're excited to have OSF as a partner who shares our company values of trust, support, and respect," said DotCom Therapy's Rachel Robinson. "The financial support and advisory role OSF Ventures offers is critically important to our success. Additionally, the Peoria-based pilot will show us how our DotCom therapists can work alongside other health care providers to coordinate comprehensive support to patients and their families."

The OSF pilot will also support the Autism Collective, a collaboration of Easter Seals Central Illinois and OSF Children's Hospital of Illinois. The Collective has a goal of connecting families with the most appropriate services to meet their needs and to ensure a coordinated, cohesive, and customized plan of care.

OSF Ventures specializes in venture optimization, partnering financially and operationally in companies that improve patient outcomes and reduce costs to health care systems. OSF Ventures is a division of OSF HealthCare. More at

OSF HealthCare is an integrated health system owned and operated by The Sisters of the Third Order of St. Francis, headquartered in Peoria, Illinois. OSF HealthCare employs more than 23,600 Mission Partners in 147 locations, including 14 hospitals –10 acute care, 4 critical access – with 2,097 licensed beds, and 2 colleges of nursing throughout Illinois and Michigan. The OSF HealthCare physician network employs more than 1,500 primary care, specialist and advanced practice providers. OSF HealthCare, through OSF Home Care Services, operates an extensive network of home health and hospice services. It also owns Pointcore, Inc., comprised of health care-related businesses and OSF HealthCare Foundation, the philanthropic arm for the organization. More at

DotCom Therapy (DCT) is the country's leading therapist-founded teletherapy company, offering the highest quality therapy services for children and families via a face-to-face online platform, Zesh, for speech therapy, occupational therapy, and behavior and mental health therapy. With over five years of experience in the teletherapy industry, DCT matches children with the right therapist(s) based on individual need, not location. Collaborating seamlessly with care teams and families, DCT teletherapists provide consistent, affordable therapy services backed by unparalleled support, compassion, and expertise.  

CONTACT: Colleen Reynolds | Media Relations Coordinator, OSF HealthCare | (309) 825-7255



AuBit announces 400,000,000 Freeway Token investment worth US$3.2m by GreenBank portfolio company

Freeway Tokens trade on popular cryptocurrency platforms Bithumb Global and Uniswap with a strictly limited supply of only 10bn. The mid-market price at 8 am GMT this morning as reported on CoinGecko ( values Staminier's holding of Freeway Tokens at approximately US$3.2m

Staminier's holding of Freeway Tokens is subject to lock-in provisions which mean that it cannot release any part of its holding until April 2021 when 60m tokens become saleable. The final proportion of 50m tokens becomes freely saleable in January 2023.

The Freeway Token is designed to fuel operations of its ground-breaking asset management platform that harnesses the power of network effects to generate increased total returns for users by distributing 80% of its trading revenues for the benefit of all users. When a user trades an AuBit-networked product, 80% of transaction revenues are automatically redistributed back to every product holder. For example, a user's holding in an AuBit-networked gold bullion product increases every time anyone, anywhere in the world, trades that same product. 

This network-enhanced asset growth brings the potential for greater total returns with no additional risk on the world's top investment products. The network effect compounds as more and more users trade on the platform. According to a study from NFX, network effects are responsible for 70% of the value of big tech unicorns in the past 23 years. 

AuBit's management team and advisors have worked at some of the largest financial and technology companies in the world including Goldman Sachs, HSBC, Fidelity, Credit Suisse, Morgan Stanley, IBM, Google, and The Prudential.

It is planned that GreenBank will provide merchant banking services to AuBit in a bid to list AuBit products on the Canadian Stock Exchange as well as other exchanges using special purpose vehicles.  The collaboration is a boost to AuBit's plan to roll-out their disruptive FinTech model to more than 180 countries worldwide, especially into Canada and the USA. 

Commenting on the investment by GreenBank's portfolio company, Sadie Hutton, Founder & co-CEO of AuBit said, "the 400,000,000 Freeway Token investment by Staminier is further proof of AuBit's billion-dollar disruptive potential in the trillion-dollar asset management industry as we focus our attention on the upcoming launch of the Freeway Platform in more than 180 countries worldwide. Independently verified simulations show AuBit users can achieve as much as 75% additional gains per year above the market benchmark, with no extra risk — something no other platform has ever been able to offer. We're confident that our collaboration with GreenBank, as well as the early acquisition of FWT, will prove beneficial for everyone." 

David Lonsdale CEO of GreenBank added, "as one of the first public companies to recognise the importance of blockchain technology in relation to financial transactions, GreenBank Capital is hugely excited about the prospects for Staminier's long term Freeway Token investment.  The multi-trillion-dollar global asset management industry continues to grow each year, but has barely changed in decades and is ideally suited for AuBit's new technology that could change asset management forever by building a true bridge from the traditional world of capital markets to the new world of digital and decentralized finance and make mass global adoption a reality.  We intend to help AuBit in that quest by pursuing with them projects to list special purpose vehicles on internationally-recognised stock exchanges as a way of allowing a wider audience of investors to gain exposure to AuBit's revolutionary products.

Here at Greenbank, one of our declared objectives (and the objectives of the investment companies in our portfolio) is to invest in and work with companies that can scale globally and have a valuation potential of at least $1b. We believe AuBit fits those criteria very well indeed".



Related Links


Kate Farms Closes $51 Million Series B; Investment Led By Goldman Sachs and Kaiser Permanente Ventures

Kate Farms produces plant-based, organic, clinically proven formulas for tube feeding to help nourish those with chronic illnesses. The company also produces nutrition shakes consumed orally for people with shorter-term or milder conditions that don't require tube feeding. Made without major allergens, the product portfolio is USDA Organic-certified, vegan, gluten-free and kosher, and is accessible in more than 95% of U.S. hospitals.

"We are excited to be backing the Kate Farms team as they continue to pave the way for plant-based nutrition in healthcare. Kate Farms' differentiated product, strong community support from both patients and providers, and widespread distribution make them a true category leader within the overall liquid nutrition industry," said Allison Berardo, a Vice President in Goldman Sachs' growth equity platform, GS Growth, who will be joining the Board of Directors at Kate Farms.

Kaiser Permanente Ventures is a national leader in strategic investing to advance healthcare innovation, having invested in more than 70 companies over the past 20 years.  Sam Brasch, Kaiser Permanente Ventures' Senior Managing Director, noted that his team was thrilled by the guidance it received from within Kaiser Permanente and beyond on the important role of plant-based nutrition, especially as it pertains to the health and well-being of patients relying on enteral nutrition support.

"Kate Farms' mission has always been to make nutrition the foundation of health so that people can live their best lives. We know first-hand that plant-based nutrition can reverse disease and prevent illness and are excited to be working alongside some of the leading hospitals, doctors and dietitians to provide a higher standard of nutrition for people with medical conditions," said Brett Matthews, Chairman and CEO of Kate Farms. "Now with the addition of our new Blue-Chip investors, we will continue to accelerate our efforts to lead the plant-based revolution in healthcare to help the hundreds of millions of people who can benefit."

The funds will help fuel Kate Farms' growth to bring its higher standard plant-based liquid nutrition to those in need, while driving overall innovation and expansion of the business. As Kate Farms continues to define the plant-based category in the medical community, the company is experiencing its fourth year of sustained growth. Other key wins include:

  • Kate Farms products are now available in more than 95 percent of hospitals around the country and are covered by Medicare, Medicaid and more than 2,000 private insurance plans.

  • In addition to being available in top-ranked adults and children's hospitals in the country, Kate Farms secured a five-year contract award issued by the Department of Veterans Affairs (VA), which makes its products available to veterans and others through government services.

  • McKesson Corporation (MCK NYSE) named Kate Farms its Supplier of the Year in 2020 for its continued product innovation, healthy product pipeline and outstanding growth.

  • Kate Farms launched three new products and formulas in 2020, including a specialty formula for children, a product to help people who suffer from weight loss due to chemotherapy during cancer treatment and a meal replacement shake that is available over the counter on and Amazon.

To learn more about Kate Farms, its mission and products, visit

Kate Farms was founded when a little girl named Kate Laver was failing to thrive because she couldn't tolerate any of the available tube feeding formulas. Her determined parents, Richard and Michelle, had the transformative idea to develop a better formula: use the highest-quality organic plant-based ingredients without the allergens found in other formulas. Today Kate is thriving, and healthcare professionals, caregivers and people with medical conditions are driving a movement to demand better nutrition. 

In 2015, successful entrepreneur Brett Matthews, who also understands first-hand the power of nutrition to heal, invested in Kate Farms, became Chairman and eventually full-time CEO. Under Brett's leadership, and with an amazing Board, Team and investors, Kate Farms is the leader in the providing plant based liquid nutrition to those with chronic conditions and less severe health needs.  

Used for tube and oral feeding, Kate Farms is eligible for insurance coverage by Medicare, Medicaid and more than 2,000 private insurance plans and a growing number of WIC1programs.Kate Farms formulas are on formulary with many leading children's and adult hospital systems across the country and are available to more than 95% of U.S. hospitals. Free of common allergens and clinically proven, Kate Farms formulas and nutrition shakes are made of easily digested organic pea protein, prebiotic soluble fiber from organic agave inulin and a clinically effective phytonutrient blend that provides antioxidants. Kate Farms flows easily through a feeding tube and is also used orally because of its great taste. Kate Farms tastes great and is also available at

For more information, visit or follow the company on Instagram, Twitter, Facebook, or LinkedIn

About Goldman Sachs Merchant Banking Division
Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment banking, securities and investment management firm. Goldman Sachs Merchant Banking Division (MBD) is the primary center for the firm's long-term principal investing activity. MBD is one of the leading private capital investors in the world with investments across private equity, infrastructure, private debt, growth equity and real estate.

About Kaiser Permanente Ventures
Kaiser Permanente Ventures, the corporate venture capital arm of Kaiser Permanente, is dedicated to forming effective partnerships with innovative companies. Kaiser Permanente Ventures invests predominantly in HCIT and services, as well as diagnostics, drug delivery and therapeutic medical devices.

1 WIC is a registered service mark of the U.S. Department of Agriculture for USDA's Special Supplemental Nutrition Program for Women, Infants and Children.

Media Contact:
[email protected]
215 439 7776

SOURCE Kate Farms

Related Links


Co-Founder of YouTube Chad Hurley Announces Investment in CLMBR, Marking His First Venture into the Connected Fitness Space

DENVER, Nov. 12, 2020 /PRNewswire/ -- Today CLMBR - a leader in connected fitness technology - announced the addition of Chad Hurley, co-founder and former CEO of YouTube, to its board of advisors. Hurley's role at CLMBR will have a particular focus on the buildout of a cutting edge content ecosystem for the brand. He also joins venture capital and private equity firm KBW-Ventures; exercise physiologist and CEO and Founder of 22 Days Nutrition, Marco Borges; and others as an investor in a seed round that will be used to support the launch and delivery of CLMBR Connected and CLMBR Pure vertical climbing machines.

A former cross-country and track and field runner, Hurley was searching for an interesting alternative to running on a treadmill amid the pandemic and stay-at-home orders. He read about how star athletes like LeBron James swear by vertical climbing and discovered CLMBR, the world's first connected vertical climbing machine.

"The pandemic put into perspective the importance of prioritizing my health, and vertical climbing is an impactful full-body exercise that has made a big difference throughout my recent fitness journey. Not only is the CLMBR team reimagining at-home exercise equipment, it is working to democratize the fitness experience for all consumers through its upcoming advanced and diverse content platform. I'm looking forward to providing my expertise within the content streaming space to help CLMBR create a one-of-a-kind user experience that matches its one-of-a-kind machine," said Chad Hurley, co-founder of YouTube.

CLMBR is an ergonomic and innovative vertical climbing apparatus and the first vertical climber to feature a large-format touch display with on-demand, instructor-led classes. The patent-pending design has a high-quality build, minimal level of required maintenance, and features an integrated audio system that can fill an entire room with sound, enhancing excitement for the user. It also offers a state-of-the-art companion app to display key metrics including vertical feet climbed and workout targets reached. 

"When Chad reached out with interest in joining the CLMBR team, we were very eager to tap into his expertise and background in delivering content to a wide range of consumers," said Avrum Elmakis, founder and CEO of CLMBR. "CLMBR is disrupting the way people exercise and offers a new take on a classic machine. We aim to go a step further with our in-app experience and unique content platform. A lot of our time is now spent at home, and we want to make sure that consumers have access to a range of fitness experts at home and can walk away from our machine feeling connected to a community of likeminded people on their fitness journeys. With the addition of Chad, we're confident that we'll be able to deliver a workout experience unmatched by any others in the connected fitness space. We're excited to share more in the coming months."

Sign up for pre-order notification of CLMBR Connected for home and CLMBR Pure for commercial use at

CLMBR is an ergonomic and innovative vertical climbing machine. It's the first vertical climber to feature a large-format touch display with on-demand, instructor-led classes. CLMBR's patent-pending design has a high-quality build, a low level of required maintenance, and is easy to move – making it perfect for commercial or at-home use. The machine is beautiful with an open structural design that leaves the user's views unobstructed, supporting a natural athletic posture. It also offers the latest user interface technology and state-of-the-art companion app that provides on-demand climbing classes and displays key metrics to maximize the user's experience, including vertical feet climbed and workout targets reached. Unlike traditional climbing machines, CLMBR reaches for new heights and is ideal for any modern user. CLMBR is safe for most ages and levels of ability. To pre-order and learn more, please visit


Related Links


DRIVE by DraftKings Appoints New CEO and Expands Investment Portfolio

BOSTON, Nov. 12, 2020 /PRNewswire/ -- DRIVE by DraftKings has appointed Meredith McPherron as its CEO and Managing Partner. DRIVE, a multi-stage venture capital firm that invests in SportsTech and Entertainment, is also pleased to announce the addition of several new startups to its investment portfolio.

Prior to joining DRIVE, McPherron served as a Venture Partner with Glasswing Ventures, an early stage venture capital firm investing in the next generation of AI, cybersecurity and intelligent enterprise startups. She also served as a mentor for the MIT DesignX accelerator, an Entrepreneur in Residence at the Harvard Innovation Lab, an Innovation Fellow at the Harvard School of Engineering & Applied Sciences, and was a board member and close strategic advisor for BFY Brands, which sold to PepsiCo in February.

"I look forward to leading DRIVE by DraftKings as an organization that continues to discover and fuel the next big ideas across sports, gaming and media," said Meredith McPherron, CEO and Managing Partner of DRIVE by DraftKings. "With that being said, we want to warmly welcome Guidesly, Cardless, PickUp, and Warriors International (WIN) to the DRIVE portfolio as our latest investees and companies poised for accelerated growth. Each of these companies boast founders with the drive to make their unique vision a reality. We will be actively involved in their growth by providing strategic support and connections to customers, channels and influencers."

DRIVE's mission is to push the frontier of new markets and categories revolutionizing sports, gaming and media. DRIVE's expanded investment portfolio now also includes:

  • Guidesly (Boston) is the first mobile platform connecting outdoor enthusiasts with trusted guides for fishing trips.

  • Cardless (San Francisco) helps consumer brands quickly and easily launch branded credit cards for their super fans.

  • PickUp (Brooklyn) is a fan opinion platform for publishers of all sizes to make their content more interactive, fun and shareable.

  • Warriors International - WIN (Boston) is an esports league and community platform that provides world-class tournaments and entertaining content for gamers, creators and fans.

With COVID restricting the number of fans at live sporting and entertainment events, leagues, teams, broadcasters, athletes and gamers have sought alternative ways to connect with fans from afar, relying on technology to enhance the at-home experience. Technology also offers sports entities new opportunities to monetize valuable assets, create new revenue streams, and find innovative ways to activate partners and sponsors. The esports industry, for example, saw significant growth in key performance indicators including viewership and social media during the pandemic.

DRIVE's portfolio companies allow users to remain connected to their favorite teams or activities while also providing new revenue opportunities for brands, both incredibly important during these unprecedented times.

"The ongoing coronavirus pandemic has expedited technological advancements out of sheer necessity, especially in sports, gaming and media sectors where fan engagement and interaction are the lifeblood," McPherron said. "Each of these investments fits into the areas we've identified as major drivers across those sectors not only today, but tomorrow as well."

The Strategic Advisory Board now includes Peter Blacklow of Boston Seed Capital, Peter Boyce of General Catalyst, Ryan Moore of Accomplice, and Jason Robins of DraftKings.

"As DRIVE embarks on a new chapter and direction, the company could not be in better hands than with Meredith McPherron taking the reins," said Jason Robins, CEO and co-founder of DraftKings. "The SportsTech and Entertainment communities have a true strategic resource in DRIVE, which will empower portfolio companies to accelerate growth and realize their full potential."

For more information on DRIVE by DraftKings please visit

About DRIVE by DraftKings

DRIVE by DraftKings is a multi-stage venture capital firm that invests in SportsTech and Entertainment.  Our founding partners include DraftKings, General Catalyst, Accomplice and Boston Seed Capital. DRIVE is unique among investment firms as a fully independent and highly strategic venture capital partner. Together with founders pushing the frontier of new markets and categories, we will drive the future of sports, gaming and media. We are inspired by people with the drive to unlock their full potential and chase big ideas.

Media Contact

[email protected]

SOURCE DRIVE by DraftKings

Related Links


Livestorm Raises $30M to Accelerate Development of Its Video Communications Platform and Expansion Into North America

PARIS, Nov. 12, 2020 /PRNewswire/ -- Livestorm, which is transforming online events with the first video communications platform that runs completely in a mobile or desktop browser, announced today that it has raised a $30M Series B funding round to accelerate product development and its expansion into North America. The round was led by Aglaé Ventures and Bpifrance Digital Venture, with participation from Raise Ventures and IDInvest. This brings Livestorm's total amount raised to date to $35M.

The four-year-old company, based in Paris, grew its revenue by 8x since its last funding round in 2019 and tripled its head count to 50+. Currently, about one-third of Livestorm's customers are in the U.S., which is the fastest-growing region for the company.

Livestorm's platform allows businesses to host meetings or webinars from two to thousands of participants in a browser (desktop or mobile). Livestorm can adapt to any kind of online event (online training courses, product demos, conferences), and manage it from end to end, from promotion through post-event ROI analysis. More than 3,500 companies from startups to Fortune 500 companies rely on Livestorm, including brands such as Shopify, Honda and Sephora.

"We immediately recognized that Livestorm is the HubSpot for video communications," said Cyril Guenoun, Partner at Aglaé Ventures. "Video and online events have become essential in 2020 and are here to stay. The Livestorm platform thrives in this environment, providing a seamless solution for meetings and events with all the connectors that marketing, sales, customer service and HR pros need to make video a tightly integrated part of their communications strategies. We're really excited about the growth potential for Livestorm, especially as they expand their footprint in the U.S."

Livestorm addresses four main issues that have plagued traditional online meeting and event platforms such as Zoom, Microsoft Teams and GoToWebinar:

  • User experience and complexity: Other platforms often require an app for hosts and attendees, causing barriers to joining events, especially for those on a mobile device or restricting networks. Livestorm is designed to operate completely in a mobile or desktop browser, with no apps needed for anyone, with minimal IT configuration.

  • Event setup in minutes not hours: Many platforms focus only on the video experience but Livestorm helps run any external or internal event from end-to-end. Events are ready out of the box with features for promotion, hosting, reporting and retargeting. Customers can set up their events with landing page creation tools, send promotional emails, automate email reminders or create custom registration forms, all in one platform. 

  • Capturing event data to leverage for future marketing: Traditional webinar platforms at best may generate a spreadsheet of registration data. Livestorm offers advanced reporting to measure your events engagement and understand your audience. That data can be leveraged by third-party integrations, including Zapier, for future marketing campaigns.

  • Security: Installing applications often comes with a risk. Working on a browser offers, by design, advantages including having multiple layers of security from the browser itself.

Livestorm will be using the funding to rapidly increase its marketing presence and scale its go to market strategies toward mid-market and enterprise in the U.S., while hiring aggressively both in Europe and the U.S.

Livestorm Co-founder and CEO Gilles Bertaux created Livestorm after working as part of a marketing group that struggled to promote and measure ROI for online events. Bertaux found he was spending most of his time creating landing pages, promoting events and troubleshooting attendees' connection issues, and did not have the means to connect online events to real business outcomes. 

"We created Livestorm to address the need for more robust video communications tools, and saw great market traction," said Bertaux. "In 2020, as hordes of companies turned to online events and meetings for the first time due to COVID-19, Livestorm was well-positioned to earn that business. Over the next year, we want to build a Slack-like marketplace of plugins for our platform, an ecosystem where developers will be able to easily build on top of Livestorm."

In 2021, Livestorm plans to once again triple its head count, hiring 100 more professionals across engineering, sales, support and marketing. "We are ramping up our U.S. presence quickly," said Bertaux, "to take advantage of all the demand."

About Livestorm

Livestorm is transforming online events, with the easiest way to incorporate video into any type of communication, to attract, engage and educate their audience. Livestorm is the first video communications platform that allows businesses to host meetings, webinars or events with two to thousands of people completely in a mobile or desktop browser. The Livestorm platform manages online events from end to end, from promotion and registration through post-event ROI analysis. More than 3,500 companies from startups to Fortune 500 companies rely on Livestorm, including brands such as Shopify, Honda, Spendesk, Front, Sephora, and Revolut. Learn more at

About Bpifrance and Bpifrance Digital Venture

Bpifrance is the French national investment bank: it finances businesses - at every stage of their development - through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy.) to help entrepreneurs meet their challenges (innovation, export…)

Bpifrance Digital Venture is the VC team within Bpifrance, dedicated to digital and tech companies aiming to become global leaders on their market. It focuses on Seed and Series A/B stages. With €700 million under management, the team backed nearly 90 companies and had 15 exits since 2011. Amongst the investments made by Bpifrance Digital Venture team are Teads (bought by Altice), Talentsoft, Netatmo (Legrand), Meilleurs Agents (Axel Springer), Balyo, Manomano, Evaneos, Openclassrooms, Cardiologs Technologies, GitGuardian, Strapi, Numworks.

For more information, please visit: and

Follow us on Twitter: @Bpifrance - @BpifranceDV - @BpifrancePresse

About Aglaé Ventures

Aglaé Ventures is a venture capital firm based in Paris, New York and San Francisco backed by Group Arnault, the controlling shareholder of LVMH, global leader in luxury goods.Aglaé Ventures invests from €100K up to €100MM in asset light activities and fast growing tech companies at all stages. Groupe Arnault backed companies include Netflix, Spotify, Airbnb, Slack, Lyft, Noom, BackMarket and others.

About RAISE Ventures

RAISE Ventures is a Venture Capital structure dedicated to innovative startups in France and in Europe. RAISE Ventures aims to support entrepreneurs using disruptive technologies and business models and to help them develop, especially internationally.

RAISE Group, founded by Clara Gaymard and Gonzague de Blignières, is based on a unique funding model that combines profitability with philanthropy. The different investment teams pass on 50% of their carried interest to the Endowment Fund RAISESHERPAS. Its model, the first of its kind in France, is at the heart of a virtuous ecosystem bringing together large corporate and institutional shareholders, mid-sized firms and the fledgling entrepreneurs.

More information :

Media contact:

Michelle Faulkner
[email protected]

Related Images

Livestorm logo

Livestorm founders
From L to R: Gilles Bertaux, Co-founder and CEO; Robin Lambert, Co-founder and CPO; Tom Forlini, Co-founder and CTO; Vincent Garreau, Co-founder and Lead Front-End.

Related Links

SOURCE Livestorm


Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases

CAMBRIDGE, Md. and SUZHOU, China, Nov. 12, 2020 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced $46M in investments secured to date and the appointment of Frederick Beddingfield, MD, PhD as Chief Executive Officer. Kira is backed by a syndicate of leading global life science venture firms including Quan Capital, 6 Dimensions Capital, Qiming Venture Partners, and Sinopharm Capital and plans to rapidly advance a pipeline of novel therapies designed to achieve better, longer lasting immune modulation.

"Kira has developed a scientifically innovative platform technology and a breakthrough approach to developing transformative therapies for patients with complement-mediated diseases," said Peter Wirth, senior advisor and board member of Kira Pharmaceuticals and Venture Partner at the lead investor Quan Capital. "We are pleased to welcome Frederick at a critical time for the organization. His experience and expertise in building and guiding research organizations will be invaluable as Kira prepares to advance a robust pipeline of complement targeted therapies to the clinic."

"Kira's founding team has developed an intelligent drug discovery platform driving the development of novel compounds with the ability to overcome the challenges of complement drug discovery and modulate the complement system in new and thoughtful ways," said Dr. Beddingfield, CEO, Kira Pharmaceuticals. "I am honored and excited to join Kira on its mission to advance several first-in-class therapies for the benefit of patients in desperate need of treatment options."

With a therapeutic focus on inflammatory and autoimmune diseases and oncology, Kira has plans to advance three complement-targeted therapies to the clinic over the next 18 months. Kira's most advanced program, P014, is a first-in-class biologic drug with a unique mechanism of action designed to inhibit both upstream and downstream complement targets. By regulating two separate rate-limiting steps in the complement activation cascade that are critical for disease development, P014 provides a powerful, and potentially safer approach to complement inhibition. P014 has also been engineered with an extended half-life and potency, with the opportunity for self-administration at home.

Founded by some of the foremost experts in complement biology, Kira Pharmaceuticals has designed its LOGIC drug discovery platform (Lead identification, Optimization and attribute Generation, In vivo Confirmation) to overcome the challenges of complement drug discovery. The complement system is a key driver and amplifier of inflammation and tissue damage in many human diseases but is complex and historically difficult to target.

"This drug discovery platform is based on technology and animal models licensed from the University of Pennsylvania and I am very pleased to see this effort to translate our research findings into medicine for patients in need," said Wenchao Song, PhD, scientific co-founder and Chair of the Scientific Advisory Board of Kira Pharmaceuticals. Song is also a professor of Systems Pharmacology and Translational Therapeutics in the Perelman School of Medicine at University of Pennsylvania. 

Dr. Beddingfield joins Kira with nearly 20 years of biopharma experience. Beddingfield will lead Kira as the company moves quickly to expand the impact of its LOGIC platform while advancing a portfolio of complement-targeted therapies into the clinic. Most recently, Dr. Beddingfield was founder and CEO of Sienna Biopharmaceuticals, a company developing topical and systemic therapies for inflammatory and immune-mediated skin diseases. Prior to Sienna, he served as Chief Medical Officer at both Kythera and Allergan Medical. Dr. Beddingfield is board certified in Dermatology, Mohs Micrographic Surgery, Cutaneous Oncology and Emergency Medicine. He is also an Associate Clinical Professor at UCLA. Dr. Beddingfield received his MD from the University of North Carolina (UNC)-Chapel Hill and PhD from Pardee RAND Graduate School.

About Kira Pharmaceuticals
Kira Pharmaceuticals is a biotechnology company developing complement-targeted therapies to treat immune-mediated diseases. Enabled by its LOGIC drug discovery platform, the company is committed to advancing first-in-class and best-in-class therapies to transform the lives of patients with complement-driven diseases. With offices in Cambridge, Massachusetts and an R&D center in Suzhou, China, Kira Pharmaceuticals is committed to establishing a global footprint and advancing life-changing therapies to patients around the world.

For more information, please visit

SOURCE Kira Pharmaceuticals

Related Links


Solv Raises $27 Million To Build A National Scheduling Network And Make Convenient Healthcare Accessible To More Americans

The funding round helps Solv give consumers unprecedented access to same-day doctors' visits, virtual visits, chat-based healthcare, and COVID testing - across all 50 states. As part of the raise:

  • Theresia Gouw from Acrew Capital, joins Bill Gurley (Benchmark), James Slavet (Greylock) and Solv co-founders Heather Fernandez & Daniele Farendi on the Board of Directors.

  • MultiCare will now serve as a strategic investor and MultiCare EVP & COO Florence Chang will be joining Solv's industry advisory board.

  • Beth Frensilli is joining the team as Solv's Chief Legal Officer. Prior to joining Solv, Beth was part of the team that scaled One Medical. She brings experience across financial services and healthcare companies to the Solv team to accelerate growth.

  • Dr. Rob Rohatsch has been appointed as Solv's first Chief Medical Officer. As an ER doctor and entrepreneur, Dr. Rohatsch most recently served as the CEO of Banner Urgent Care and previously was the co-founder and CEO of PhysicianOne Urgent Care.

  • Solv will expand its speciality areas to include primary care, mental health and women's health to enable more healthcare options to consumers.

The raise builds upon Solv's recent acceleration of growth including:

  • New features in the Solv app have helped millions of Americans discover local COVID-19 testing sites through its national network of urgent care clinics. As a result more than 2 Million COVID-19 tests have been booked through Solv.

  • A nealy 6x year-over-year increase in Solv app and website traffic from consumers -- 6.3 Million visitors in October 2020 compared to 1.1 Million visitors in October 2019, which demonstrates how more patients are choosing Solv as the starting point for accessing convenient healthcare from a mobile device.

  • New partnerships with local and state governments, including the State of Michigan and City of Seattle, to increase COVID-19 testing access using online scheduling, digital registration and waitlist queuing.

"We're seeing dramatic shifts in the way healthcare is being accessed today. Until recently, it's been a one size fits all experience where you must book an appointment weeks in advance, drive to the office, wait and only then see a doctor. COVID-19 has pulled the future forward. Healthcare has shifted to a digital-first experience, allowing Americans to engage with healthcare from their homes without disruption in their daily lives," said Heather Fernandez, CEO and co-founder of Solv. "Solv is leading the charge to make sure that innovative providers can offer a digital-first experience, and consumers get more access to what they need, when they need it, from their phones."

Overnight COVID changed how consumers access healthcare. Patients have gone online to address the majority of their needs. More appointment scheduling, video visits, electronic prescriptions, doctor chats and bill payment is happening online than it ever has before. This consumer shift has created the need for providers to adopt modern tools that address patients' digital-first expectations. As a result, providers have quickly turned to Solv's software to meet convenient care demands and have rolled online scheduling, telemedicine, chat, and COVID test queuing.

According to Solv:

  • Since March of 2020 there have been 700,000 telemedicine appointments booked on Solv versus just 9,000 booked in the entirety of 2019.

  • Across their network of providers, online scheduling of appointments has grown from 22% of all doctor visits in March 2020 to nearly 60% of all doctor visits in August 2020.

  • 56% of people still skip visiting the doctor over a health concern because it was inconvenient to book an appointment.

"I've had the honor to have worked closely with the dedicated and ambitious Solv team since 2017. I'm thrilled to further extend my partnership and join the board as they are not only rethinking what the healthcare industry should look like, but taking major strides in transforming it so that Americans don't have to sacrifice their health just because it wasn't easy to get a doctors appointment," Theresia Gouw, Founding Partner of Acrew Capital. "Solv's massive growth this year proves that patients nationwide are embracing the move to digital healthcare so that they don't have to wonder what doctor to go to, where they should be seen and how much it would cost them. Solv is enabling consumers to get the care they need, when they need it, which is truly remarkable."

To conveniently book a telemedicine appointment on Solv, or to find a nearby COVID-19 test site, please visit

About Solv

Solv is a consumer-focused healthcare app that connects patients to a robust network of convenient healthcare providers, empowering you to simplify your everyday healthcare needs. Solv partners with high-quality care providers across the country to make convenient care simple, friendly and transparent for consumers, the way it should be. For providers, Solv's technology improves the quality of service and the performance of their practice. For consumers, the Solv app utilizes this provider network to unlock same-day appointment availability, virtual visits and cost transparency in just a few taps from a mobile phone. Solv puts you in control of your healthcare by letting you know where you can go, when you'll be seen, and how much it will cost. Solv is building a world where everyone, nationwide, can access healthcare that is convenient and affordable.

About Acrew Capital

Acrew Capital is an early stage venture firm that engages in long term partnership with world-class teams uniquely suited to solving big, hard problems. We believe the best investment decisions are driven by a combination of depth of conviction and diversity of perspective and that investment should be tailored to the specific needs of each founding team.  Acrew investment themes include Cybersecurity and Infrastructure Modernized, Financial Services Rebuilt, Work Reimagined, Data Interconnected and Community Activated. The Acrew founding team previously worked together at Aspect Ventures and combines experience from Accel, Brown University, Google, Greycroft, and Imperva. Current Acrew team investments include Cato Networks, Chime, Exabeam, Pie Insurance, Silverfort,, and HotelTonight/AirBnB. Collectively, the firm's track record includes 5 IPOs, over 20 successful acquisitions and over 100 rounds of follow-on capital raises, resulting in over $20 billion in market value created and over $1B in returns to investors. For more information visit

SOURCE Solv Health

Related Links


Synendos Therapeutics Raises CHF 20 Million in Series A Financing

BASEL, Switzerland, Nov. 12, 2020 /PRNewswire/ -- Synendos Therapeutics (Synendos), a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (CNS) disorders, announces it has raised  CHF 20 million in a Series A financing co-led by Kurma Partners and Sunstone Life Science Ventures with participation from BERNINA BioInvest, Schroder Adveq, High-Tech Gründerfonds, Lichtsteiner Foundation, Essential Investments, Zürcher Kantonalbank and private investors.

Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body's endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. The endocannabinoid system is a key neuromodulator system in the CNS involved in regulating various physiological and cognitive processes. Synendos' newly developed selective endocannabinoid reuptake inhibitors (SERIs) act by increasing the levels of endogenous cannabinoids in a self-limiting mode of action, representing an innovative and potentially safer therapeutic approach to CNS disorders associated with anxiety, mood and stress-related disorders. 

Incorporated in April 2019, Synendos Therapeutics was spun out of the University of Bern and the research consortium, NCCR TransCure. The novel technology stems from 10 years of solid research on endocannabinoid biology and pharmacology carried out at the university led by co-founders, Professor Jürg Gertsch and Dr Andrea Chicca.  The research team led by Professor Jürg Gertsch is dedicated to drug discovery in the endocannabinoid system.

Currently in preclinical development, proceeds from the financing will be used to complete this development and advance Synendos' lead drug candidate through safety and proof of concept studies in a relevant and well-defined disease indication, as part of early/initial clinical trials. 

Dr Andrea Chicca, co-founder and CEO of Synendos Therapeutics, commented: "There are considerable neuropsychiatric complications and comorbidities associated with CNS disorders and, in today's world, an increasing prevalence of anxiety-related conditions. Despite this, it has been 25 years since a new drug was approved for the treatment of neuropsychiatric disorders. This highlights the urgent need for new safe and effective treatments in this area and underpins Synendos' mission to focus on the development of a novel drug technology to help combat anxiety, mood and stress-related disorders. We are very pleased to have attracted such a strong syndicate of world-class investors.  In the validation of our science, they bring much more than just financing and will enable us to work towards reaching a clinical inflection point with an efficient and clearly-defined path."

Søren Lemonius, Managing Partner at Sunstone Life Science Ventures, said: "Synendos Therapeutics represents a perfect match with the type of investment opportunities Sunstone looks for – a novel approach to a biology relevant for patients struggling with severe diseases, such as fear and anxiety, but not yet well explored by the established industry. We are very excited about our new investment in Synendos Therapeutics and look forward to collaborating with the three founders and the new board in the years to come."

Peter Neubeck, Partner at Kurma Partners, added: "It is truly exciting to see where we have come as a team of founders and investors combining the scientific excellence and vision with a sound development plan and financial structuring resulting in the creation of Synendos, a company with the potential to fundamentally change the treatment paradigm of complex neuropsychiatric conditions."

Dr Peter Neubeck of Kurma Partners, Dr Søren Lemonius of Sunstone Life Science Ventures and Dr Bettina Ernst of Bernina Bio Invest will join Synendos Therapeutics CEO, Dr Andrea Chicca, and co-founder, Dr Simon Russell on the Board of Directors.

Synendos has been part of BaseLaunch, the Basel Area based incubator and accelerator that helps build companies from inception through to Series A funding, which has provided key early stage financial and operational support in the early development of the Company.

About Synendos Therapeutics

Synendos Therapeutics is a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (CNS) disorders. Incorporated in April 2019, Synendos Therapeutics was spun out of the University of Bern and the drug discovery consortium, NCCR TransCure.  The company's novel technology stems from 10 years of solid research on endocannabinoid biology and pharmacology carried out at the University of Bern by co-founders, Professor Jürg Gertsch and Dr Andrea Chicca, and centres around the development of selective endocannabinoid reuptake inhibitors (SERIs). SERIs act by increasing the levels of endogenous cannabinoids in a self-limiting mode of action, representing an innovative and potentially safer therapeutic approach to CNS disorders, associated with anxiety, mood and stress-related disorders, than is currently available.

About SERIs

SERIs are first-in-class endocannabinoid system modulators that mildly and selectively increase endogenous cannabinoids levels by inhibiting a newly identified drug target. SERIs act with a self-limiting mechanism of action that enables a fine-tuned modulation of synaptic transmission in major neuronal circuits in the CNS. The new mode of action of SERIs represents an innovative and potentially safer therapeutic approach to CNS disorders associated with anxiety, mood.

About Kurma Partners

Founded in July 2009, Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I through III and Kurma Diagnostics, as well as via strategic partnerships with prestigious European research and medical institutions. Innovative projects from Academia and research institutions, aspiring to meet unmet medical need is an important pillar of the firm's investment strategy, a second is venture capital financings of innovative young companies in Biotech and MedTech; all with a strong focus on innovative drug development approaches.

About Sunstone Life Science Ventures

Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Sunstone Life Science Ventures focuses on developing and expanding early-stage Life Science companies with strong potential to achieve global success in their markets. Since the inception, Sunstone Life Science Ventures has invested in more than 50 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. Managing total funds of approx. €500 million, Sunstone Life Science Ventures is one of the largest Nordic venture capital investors.

SOURCE Synendos


Wednesday, November 11, 2020

European synthetic biology company Octarine raises $1.8M USD in...

Today, Octarine Bio ApS (“Octarine” or the “Company”), a synthetic biology company developing biosynthetic platforms for cannabinoids, psychedelics and their novel improved derivatives announced the successful closing of Seed financing led by the Danish State Growth Fund (Vækstfonden) with participation from Enexis AB, Oskare Capital and cannabis and psychedelic industry veteran Bruce Linton. This latest financing comes shortly after the company closed a pre-seed round earlier this year, bringing the total amount raised by the company to over $1.8M USD.

“In these uncertain times we’re thrilled to be able to close our next round of financing” said Octarine Co-founder and CEO Nethaji Gallage. “We’re excited to welcome new investors on board but also very pleased to receive follow-on investment from existing investors and greatly appreciate their continued support and belief in our team and the mission.”

“Octarine has shown significant progress since our first investment in the beginning of 2020” said Lene Gerlach, investment manager at Vækstfonden, “and we’ve experienced a great interest in the company both from investors and large market players. They, as well as us at Vækstfonden see great potential in Octarine’s platform technology, which is based on ground-breaking research from the University of Copenhagen and Technical University of Denmark. We believe Octarine will play an important role in improving both the manufacturing and the characteristics of complex natural compounds.”

“We identified Octarine in April of 2019 as a company with a very high potential to disrupt the medical cannabis market through its set of proprietary novel compounds. We are happy to be joining forces with Vækstfonden, Enexis and other business angels, who share the same vision as Oskare Capital on Octarine’s potential in the cannabinoid and psychedelic space,” said Alexandre OUIMET-STORRS, Co-Founder and Managing Partner of Oskare Capital.

Proceeds from the round will be used to obtain important pre-clinical validation of the company’s novel, improved cannabinoid derivatives in in vivo animal models. In vitro data has demonstrated significant improvements in solubility, stability, and bioavailability of these molecules over natural cannabinoids and the company expects to be able to generate a lead candidate for further clinical development.

“Solubility, stability, and bioavailability are significant issues currently limiting the therapeutic application of cannabinoids” said Octarine Co-founder and CSO Nick Milne. “With the improved derivatives in our pipeline we’re confident that we can realise the full potential of cannabinoids to treat a range of debilitating conditions.”

Proceeds will also be used to continue development of the company’s fermentation-based production platforms for pharmaceutical-grade psychedelics including psilocybin and a range of other rare and novel derivatives. These platforms will be used to supply molecules for strategic partners as well as for Octarine’s own drug development efforts.

About Octarine

Octarine’s mission is to solve our greatest health challenges by enabling innovative cannabinoid and psychedelic therapeutics. Many neurological and psychological conditions are poorly served by current drugs, leaving physicians, patients, and their families desperately seeking alternative therapies, sometimes illegally. Cannabinoids and psychedelics are poised to offer breakthrough therapies for these debilitating conditions, but to realize the full potential of these molecules, issues with their production and undesirable properties must first be solved.

Octarine is perfecting a biological approach to producing improved & novel cannabinoid and psychedelic molecules with tailored modes-of-action. Our proprietary technology combines synthetic biology, yeast fermentation and enzymatic derivatization to develop IP protected drug candidates that are validated in pre-clinical models.

Octarine was founded in September 2018 by Nethaji Gallage (CEO) and Nick Milne (CSO) based on foundational research conducted at the University of Copenhagen and Technical University of Denmark (DTU). Octarine is also an alumnus of the BioInnovation Institute, an initiative run by the Novo Nordisk Foundation.

For more information visit

About Oskare Capital

About Enexis

About Vækstfonden

About BioInnovation Institute

Share article on social media or email:


Kennedy Capital Enters Aeronautics Space with Coveted SpaceX Secondary Market Opportunity

CARLSBAD, Calif., Nov. 11, 2020 /PRNewswire/ -- Kennedy Capital is making headway in the Aeronautics space.

In honor of our great nation, Kennedy Capital announces the launch of Kennedy Defense on Veteran's Day 2020. The Patriot Intelligence Incubator based in San Francisco Bay Area is a minority and Veteran-led team facilitating the development of America's greatest operators and technologies.

With a deep bench of executives, advisors and partners both public and private, Kennedy Defense has its eyes on a MilitaryTech fund in 2021. "We will focus on the engineering and development of critical technologies and the operators who run those technologies," says Founder Zoe Nielsen, the daughter of a Vietnam Veteran and lifelong DoD Civil Servant.

Kennedy Defense has identified mission-driven initiatives in aerial technologies, cyber security, communications, Veteran job force re-entry training and "career creation", re-shoring manufacturing jobs, and VA Healthcare reform in partnership with Kennedy Bio.  

Kennedy Capital is currently engaged as strategic advisor for a second transaction in recent months of available SpaceX shares up to $200MM in valuation. Kennedy Capital provides marketing services for the offering brokerage based in Southern California.

About Kennedy Capital: 

Kennedy Capital is an independent advisory firm specializing in mergers and acquisitions, venture capital and go-to-market resources. The firm serves companies across a wide spectrum of sectors including healthcare, biotech, environmental, artificial intelligence, aeronautics, software, and defense intelligence.

Kennedy Capital is founded and led by Zoe Nielsen and includes a deeply experienced team of M&A professionals, corporate development professionals, technology developers, go-to-market strategists, brand builders and operational partners focused on hyper growth of early stage businesses. The Company also runs Kennedy Capital Accelerator, which is located in the San Francisco Bay Area, and invests time, talent and expertise in companies across a variety of areas.

The Kennedy Capital headquarters is in Marin County, California, with additional offices in Carlsbad, California, West Palm Beach, Florida, Portland, Oregon and Austin, Texas. 

Please visit:

Zoe Nielsen
[email protected]

SOURCE Kennedy Capital


Endpoint Announces New $40 Million Investment From First American to Expand Digital Real Estate Closing Platform

EL SEGUNDO, Calif.--()--Endpoint, a digital title and escrow company that provides a re-imagined closing experience for buyers, sellers, and their real estate agents, announced today an additional investment of $40 million from its parent company, First American Financial Corporation, a leading provider of title insurance, settlement services and risk solutions for real estate transactions. This investment brings the total funding received to date to $70 million, and will help accelerate Endpoint’s strategic hiring plans, proprietary technology development, and expansion into new U.S. markets.

“Endpoint’s early success reflects First American’s 130-year history of leading the title and settlement industry in enhancing the customer experience,” said Dennis Gilmore, CEO of First American Financial Corporation. “Our increased investment affirms our commitment to developing innovative, state-of-the-art technologies that improve the process of transacting real estate.”

Launched in Seattle, Endpoint surpassed its growth targets in the market and has since expanded operations into Southern California and Arizona. The company has doubled its employee base this year and is currently rolling out enhancements to its platform that further simplify transaction management and improve accessibility from any device.

“Today's home buyers and sellers live, work and play predominantly online where they expect a certain level of convenience and speed. Endpoint combines innovative technology with the expertise of experienced escrow officers and provides a digital compass for the most significant purchase of a home buyer’s lifetime,” said Scott Martino, CEO of Endpoint. “Our team is committed to supporting real estate agents and their clients as they navigate this process, while rapidly and conveniently completing their transactions.”

The investment will accelerate Endpoint’s geographic expansion and escrow automation development, enabling an increasingly secure and efficient settlement service. These efficiencies enable Endpoint’s teams to recapture time, which is then invested in providing better customer service to real estate agents, transaction coordinators, home buyers and sellers.

“There are a number of companies attempting to deploy technology to speed up the digitization of the real estate transaction,” said Paul Hurst, Managing Director, Venture Investments at First American Financial Corporation. “Endpoint has already validated the demand for, and the functionality of, its product and is now broadening its focus to fundamentally simplify and automate the escrow process across all states, with the support of First American.”

Endpoint’s digital title and escrow platform offers tools across its web, iOS and Android apps that help real estate agents grow their repeat and referral business. With a completely revamped interface launched earlier this month and new features, including optimized transaction management and activity tracking, Endpoint enables real estate professionals to deliver an enhanced closing experience for their home buyers and sellers.

About Endpoint

Endpoint is a digital title and escrow company, built from the ground up to deliver a re-imagined closing experience for real estate agents and their buyers and sellers. Through its digital platform, Endpoint keeps everyone effortlessly and securely in the know throughout the transaction, while providing a simplified real estate closing from start to finish. Endpoint was founded in 2018 with a diverse team of digital natives and industry veterans. The company is headquartered in El Segundo, California, with offices and operations in Washington, California and Arizona. For more information, please visit

About First American

First American Financial Corporation (NYSE: FAF) is a leading provider of title insurance, settlement services and risk solutions for real estate transactions that traces its heritage back to 1889. First American also provides title plant management services; title and other real property records and images; valuation products and services; home warranty products; property and casualty insurance; banking, trust and wealth management services; and other related products and services. With total revenue of $6.2 billion in 2019, the company offers its products and services directly and through its agents throughout the United States and abroad. In 2020, First American was named to the Fortune 100 Best Companies to Work For® list for the fifth consecutive year. More information about the company can be found at


Echo Health Ventures Introduces New Innovation Alliance Bringing Together Three National Health Care Leaders to Collectively Invest in Transforming Health Care

The EIA further validates Echo's unique model and will accelerate our work with leading entrepreneurs -Rob Coppedge, CEO Tweet this The ...